Fresenius Medical Care AG & Co. KGaA (ETR:FME – Get Rating) has been given a €75.00 ($80.65) price objective by stock analysts at UBS Group in a research note issued to investors on Tuesday, Borsen Zeitung reports. UBS Group’s price objective points to a potential upside of 24.17% from the company’s previous close.
Several other research analysts have also weighed in on FME. JPMorgan Chase & Co. set a €48.70 ($52.37) target price on Fresenius Medical Care AG & Co. KGaA in a research report on Monday, March 21st. Berenberg Bank set a €83.40 ($89.68) price objective on Fresenius Medical Care AG & Co. KGaA in a research note on Wednesday, March 23rd. Credit Suisse Group set a €61.00 ($65.59) target price on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Monday, February 28th. Deutsche Bank Aktiengesellschaft set a €58.00 ($62.37) price objective on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, March 22nd. Finally, Stifel Nicolaus set a €60.00 ($64.52) target price on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, February 4th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of €65.47 ($70.40).
ETR:FME traded down €1.42 ($1.53) during trading hours on Tuesday, reaching €60.40 ($64.95). 605,274 shares of the company were exchanged, compared to its average volume of 704,197. The firm has a market cap of $17.70 billion and a price-to-earnings ratio of 18.25. The stock has a 50 day simple moving average of €59.61 and a 200 day simple moving average of €58.60. Fresenius Medical Care AG & Co. KGaA has a 52-week low of €50.98 ($54.82) and a 52-week high of €71.14 ($76.49). The company has a debt-to-equity ratio of 95.29, a current ratio of 1.10 and a quick ratio of 0.76.
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
- The Sherwin-Williams Company Bottoms Above Institutional Support
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
- Whirlpool Is A Steal At These Prices
- Kimberly-Clark Pops On Successful Price Pass-Through
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.